Rundu Pharma released its performance for the first three quarters, with a net loss attributable to the parent company of 54.6878 million yuan
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, Rundu Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 884 million yuan, a year-on-year increase of 0.85%. The net loss attributable to shareholders of the listed company was 54.6878 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 66.1263 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments